Learning Objectives

By the end of this chapter, learners will be able to:
1. Define membranous nephropathy and understand its pathophysiology
2. Distinguish between primary and secondary membranous nephropathy
3. Recognize the clinical presentation and laboratory findings
4. Understand the role of PLA2R and THSD7A antibodies in diagnosis
5. Describe the diagnostic approach including renal biopsy findings
6. Outline treatment strategies for different stages of disease
7. Understand the natural history and prognosis
8. Recognize complications and their management

Introduction and Definition

Membranous nephropathy (MN) is the most common cause of primary nephrotic syndrome in Caucasian adults, accounting for approximately 20-30% of cases in this population. The condition is characterized by thickening of the glomerular basement membrane due to immune complex deposition along the subepithelial aspect of the glomerular capillaries, leading to increased glomerular permeability and proteinuria.

The disease predominantly affects adults, with peak incidence occurring in the fifth and sixth decades of life, and shows a male predominance with a male-to-female ratio of approximately 2:1. While membranous nephropathy can occur at any age, it is relatively uncommon in children, where it accounts for less than 5% of nephrotic syndrome cases.

Membranous nephropathy is classified into primary (idiopathic) and secondary forms based on the underlying cause. Primary membranous nephropathy accounts for approximately 75-80% of cases and is now understood to be an autoimmune disease in most patients, with antibodies directed against specific podocyte antigens. Secondary membranous nephropathy results from various systemic conditions, infections, medications, or malignancies.

The prognosis of membranous nephropathy is variable, with approximately one-third of patients experiencing spontaneous remission, one-third maintaining stable renal function with persistent proteinuria, and one-third progressing to chronic kidney disease or end-stage renal disease. Understanding the factors that predict outcomes is crucial for making treatment decisions.

Pathophysiology

The pathophysiology of membranous nephropathy involves the formation of immune complexes along the subepithelial aspect of the glomerular basement membrane, leading to complement activation, podocyte injury, and increased glomerular permeability. The process begins with the binding of antibodies to specific antigens expressed on the podocyte surface.

In primary membranous nephropathy, the major target antigen is the phospholipase A2 receptor (PLA2R), which is expressed on the surface of glomerular podocytes. Anti-PLA2R antibodies are found in approximately 70-80% of patients with primary membranous nephropathy. These antibodies bind to PLA2R on the podocyte surface, forming immune complexes that activate complement and trigger inflammatory cascades.

A second target antigen, thrombospondin type 1 domain-containing 7A (THSD7A), has been identified in approximately 5-10% of patients with primary membranous nephropathy who are PLA2R-negative. THSD7A is also expressed on podocytes, and anti-THSD7A antibodies follow a similar pathogenic mechanism to anti-PLA2R antibodies.

The formation of subepithelial immune complexes triggers complement activation, particularly the classical pathway, leading to the generation of membrane attack complexes and complement-mediated podocyte injury. This process results in podocyte foot process effacement, loss of slit diaphragm proteins, and increased glomerular permeability to albumin and other proteins.

The characteristic morphological changes in membranous nephropathy develop progressively over time. Initially, small subepithelial deposits form along the glomerular basement membrane. As the disease progresses, the glomerular basement membrane begins to thicken around these deposits, creating the characteristic “spike and dome” appearance on electron microscopy.

The deposits contain immunoglobulins (primarily IgG4 in PLA2R-associated disease), complement components (particularly C3 and membrane attack complex), and the target antigens. The predominance of IgG4 is significant because this antibody subclass has limited ability to activate complement through the classical pathway, which may explain the relatively indolent course of many cases.

Podocyte injury in membranous nephropathy involves multiple mechanisms including complement-mediated damage, oxidative stress, and disruption of normal podocyte architecture. The podocytes undergo foot process effacement and may eventually detach from the glomerular basement membrane in severe cases, contributing to progressive loss of filtration function.

The variable clinical course of membranous nephropathy reflects differences in the intensity and duration of the autoimmune response. Patients with high levels of circulating antibodies and active immune complex formation tend to have more severe proteinuria and higher risk of progression, while those with lower antibody levels may experience spontaneous remission.

Clinical Manifestations

The clinical presentation of membranous nephropathy is typically that of nephrotic syndrome, with the insidious onset of edema, proteinuria, and hypoalbuminemia developing over weeks to months. Unlike some other causes of nephrotic syndrome, membranous nephropathy rarely presents with acute nephritic features such as gross hematuria or rapidly declining renal function.

Edema is often the presenting symptom and typically begins in dependent areas such as the ankles and feet, gradually progressing to involve the legs, abdomen, and face. The edema is usually pitting and may become severe in patients with significant hypoalbuminemia. Periorbital edema may be present but is generally less prominent than in minimal change disease.

Proteinuria is typically heavy, often exceeding 3.5 grams per day and frequently reaching levels of 10-20 grams per day in severe cases. Patients may notice foamy or frothy urine, particularly in the morning. The proteinuria is predominantly albumin, though other proteins may also be lost in significant quantities.

Hypoalbuminemia develops as a consequence of urinary protein losses and may be severe, with serum albumin levels often falling below 2.5 g/dL. The degree of hypoalbuminemia generally correlates with the severity of proteinuria and contributes to the development of edema and other complications.

Hyperlipidemia is common and often severe in membranous nephropathy, with elevated total cholesterol, LDL cholesterol, and triglycerides. The hyperlipidemia results from increased hepatic synthesis of lipoproteins in response to hypoalbuminemia and decreased clearance of lipoproteins. This contributes to increased cardiovascular risk.

Hematuria, when present, is typically microscopic and mild. Gross hematuria is uncommon and should raise suspicion for other diagnoses or complications such as renal vein thrombosis. The absence of significant hematuria helps distinguish membranous nephropathy from other forms of glomerulonephritis.

Hypertension is present in approximately 30-50% of patients at presentation and is usually mild to moderate. Severe hypertension is uncommon and may suggest secondary causes or complications. Blood pressure tends to increase with disease progression and declining renal function.

Renal function is typically normal or only mildly impaired at presentation in most patients with membranous nephropathy. Significant renal impairment at presentation may suggest advanced disease, secondary causes, or complications such as acute tubular necrosis from volume depletion.

Constitutional symptoms such as fatigue, weakness, and decreased appetite may be present and often correlate with the severity of the nephrotic syndrome. These symptoms may significantly impact quality of life and functional status.

The clinical course is variable, with some patients experiencing a relatively stable course over years while others may have progressive disease with declining renal function. Spontaneous remissions can occur, particularly in the first few years after diagnosis, but are less common with longer disease duration.

Etiology and Classification

Membranous nephropathy is classified into primary (idiopathic) and secondary forms based on the presence or absence of an identifiable underlying cause. This distinction is important for treatment decisions and prognosis, as secondary forms may respond to treatment of the underlying condition.

Primary membranous nephropathy accounts for approximately 75-80% of cases in adults and is now recognized as an autoimmune disease in the majority of patients. The discovery of anti-PLA2R antibodies in 2009 revolutionized the understanding of this condition, providing evidence for its autoimmune nature and offering new diagnostic and monitoring tools.

Anti-PLA2R antibodies are found in approximately 70-80% of patients with primary membranous nephropathy and are highly specific for this condition. The antibodies are predominantly of the IgG4 subclass and correlate with disease activity, making them useful for both diagnosis and monitoring treatment response.

Anti-THSD7A antibodies represent a second autoimmune target in primary membranous nephropathy, found in approximately 5-10% of patients who are PLA2R-negative. These antibodies are associated with a similar clinical presentation and course to PLA2R-associated disease.

A small percentage of patients with primary membranous nephropathy (approximately 10-15%) are negative for both PLA2R and THSD7A antibodies. These patients may have antibodies directed against other, as yet unidentified antigens, or may represent a distinct subset of the disease.

Secondary membranous nephropathy can result from a variety of underlying conditions, and identifying these causes is important because treatment of the underlying condition may lead to resolution of the nephropathy.

Malignancy-associated membranous nephropathy occurs in approximately 5-10% of patients, particularly those over age 65. Solid tumors are most commonly associated, including lung, breast, colon, and prostate cancers. Hematologic malignancies such as chronic lymphocytic leukemia and non-Hodgkin lymphoma can also cause membranous nephropathy.

Autoimmune diseases can cause secondary membranous nephropathy, with systemic lupus erythematosus being the most common. Lupus-associated membranous nephropathy (Class V lupus nephritis) may occur alone or in combination with other forms of lupus nephritis. Other autoimmune conditions such as thyroiditis, rheumatoid arthritis, and mixed connective tissue disease have also been associated.

Infectious causes of secondary membranous nephropathy include hepatitis B and C, syphilis, malaria, and schistosomiasis. Hepatitis B-associated membranous nephropathy is more common in endemic areas and may resolve with antiviral therapy.

Drug-induced membranous nephropathy can result from various medications including gold salts, penicillamine, NSAIDs, and certain chemotherapeutic agents. The nephropathy may resolve with discontinuation of the offending agent, though recovery may take months to years.

Other causes of secondary membranous nephropathy include thyroid disease, sarcoidosis, and exposure to certain toxins or chemicals. A thorough evaluation for secondary causes is essential in all patients diagnosed with membranous nephropathy.

Diagnostic Approach

The diagnostic evaluation of suspected membranous nephropathy requires a systematic approach to confirm the diagnosis, determine whether it is primary or secondary, and assess disease severity and prognosis. The evaluation should include clinical assessment, laboratory studies, and often renal biopsy for definitive diagnosis.

The clinical history should focus on the onset and progression of symptoms, with particular attention to the development of edema, changes in urine appearance, and constitutional symptoms. A detailed medication history is important to identify potential drug-induced causes. Family history of kidney disease or autoimmune conditions may provide relevant information.

Physical examination should assess for signs of nephrotic syndrome including edema, blood pressure elevation, and signs of volume overload. A thorough examination for signs of systemic diseases that could cause secondary membranous nephropathy is essential, including lymphadenopathy, skin rashes, joint swelling, or organomegaly.

Laboratory evaluation should begin with confirmation of nephrotic syndrome through measurement of proteinuria, serum albumin, and lipid levels. Twenty-four-hour urine collection for protein and creatinine clearance provides the most accurate assessment, though spot urine protein-to-creatinine ratio is often used for convenience.

Serum creatinine and estimated glomerular filtration rate should be assessed to determine the degree of renal impairment. Most patients with membranous nephropathy have normal or only mildly reduced renal function at presentation.

Complete blood count may reveal anemia, which can result from chronic disease or transferrin loss. Comprehensive metabolic panel should include assessment of electrolytes, liver function, and glucose levels.

Serological studies are crucial for distinguishing primary from secondary membranous nephropathy. Anti-PLA2R antibodies should be measured in all patients, as positive results strongly suggest primary disease and correlate with disease activity. Anti-THSD7A antibodies should be checked in PLA2R-negative patients.

Evaluation for secondary causes should include antinuclear antibodies, anti-double-stranded DNA, complement levels (C3, C4), hepatitis B and C serologies, and syphilis testing. Additional studies may be indicated based on clinical presentation.

Age-appropriate cancer screening should be performed, particularly in patients over age 65 or those with clinical features suggestive of malignancy. This may include chest imaging, colonoscopy, mammography, and prostate-specific antigen testing as appropriate.

Renal biopsy is often necessary for definitive diagnosis and to rule out other causes of nephrotic syndrome. The biopsy should be processed for light microscopy, immunofluorescence, and electron microscopy. The characteristic findings include thickening of the glomerular basement membrane with subepithelial deposits and a “spike and dome” appearance.

Immunofluorescence typically shows granular deposition of IgG and C3 along the glomerular capillary walls. In PLA2R-associated disease, IgG4 is the predominant subclass, and PLA2R staining may be positive in the deposits.

Electron microscopy reveals the characteristic subepithelial electron-dense deposits with basement membrane spikes projecting between the deposits. The stage of disease can be assessed based on the morphological changes, which progress from early deposits to advanced basement membrane changes.

Treatment Strategies

The treatment of membranous nephropathy has evolved significantly with improved understanding of the disease pathophysiology and the development of new therapeutic agents. Treatment decisions should be individualized based on disease severity, risk of progression, patient age and comorbidities, and response to initial therapy.

Conservative management forms the foundation of treatment for all patients with membranous nephropathy and includes supportive measures to manage the complications of nephrotic syndrome and slow disease progression.

Dietary modifications should include moderate protein restriction (0.8-1.0 g/kg/day) to reduce proteinuria while maintaining adequate nutrition, and sodium restriction (2-3 g/day) to help control edema and blood pressure. Fluid restriction may be necessary in patients with severe hyponatremia.

Diuretic therapy is often required for edema management, with loop diuretics such as furosemide being first-line agents. Higher doses may be required due to decreased drug delivery to the tubules in the setting of hypoalbuminemia. Combination therapy with thiazide or potassium-sparing diuretics may be necessary for refractory edema.

ACE inhibitors or angiotensin receptor blockers should be used in all patients unless contraindicated, as they reduce proteinuria by 30-50% and provide cardiovascular and renal protection. These agents should be titrated to maximum tolerated doses while monitoring renal function and potassium levels.

Lipid management is essential given the severe hyperlipidemia and increased cardiovascular risk. Statins are the preferred agents and should be titrated to achieve target LDL cholesterol levels below 100 mg/dL, or below 70 mg/dL in high-risk patients.

Anticoagulation should be considered in patients with severe hypoalbuminemia (albumin <2.5 g/dL) due to the increased risk of thrombotic complications, particularly renal vein thrombosis. The decision should be individualized based on bleeding risk and other factors.

Immunosuppressive therapy is reserved for patients at high risk of progression to end-stage renal disease or those with severe symptoms that significantly impact quality of life. The decision to initiate immunosuppressive therapy should consider the potential benefits and risks, including the significant side effects of these medications.

The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend considering immunosuppressive therapy for patients with persistent nephrotic syndrome after 6 months of conservative therapy, particularly those with declining renal function, severe symptoms, or high-risk features.

Corticosteroids combined with alkylating agents have been the traditional first-line immunosuppressive therapy. The modified Ponticelli regimen involves alternating monthly cycles of corticosteroids and chlorambucil or cyclophosphamide for 6 months. This regimen has shown efficacy in inducing remission and preserving renal function.

Calcineurin inhibitors, including cyclosporine and tacrolimus, have emerged as important therapeutic options, particularly for patients who cannot tolerate alkylating agents or as second-line therapy. These agents can induce remission in 60-80% of patients but require careful monitoring for nephrotoxicity.

Rituximab, a monoclonal antibody targeting CD20+ B cells, has shown promise in treating membranous nephropathy, particularly in patients with anti-PLA2R antibodies. Several studies have demonstrated efficacy comparable to traditional regimens with potentially fewer side effects.

Mycophenolate mofetil has been used as an alternative immunosuppressive agent, though studies have shown mixed results compared to other regimens. It may be useful as maintenance therapy or in patients who cannot tolerate other agents.

Treatment of secondary membranous nephropathy should focus on addressing the underlying cause when possible. This may include treatment of malignancy, control of autoimmune diseases, discontinuation of offending medications, or treatment of infections.

Monitoring and Response Assessment

Monitoring patients with membranous nephropathy requires regular assessment of disease activity, treatment response, and drug toxicity. The frequency and intensity of monitoring depend on the treatment regimen and disease severity.

Proteinuria is the primary marker of disease activity and should be monitored regularly using either 24-hour urine collections or spot protein-to-creatinine ratios. Complete remission is defined as proteinuria less than 0.3 g/day with normal renal function, while partial remission is defined as proteinuria reduction of at least 50% from baseline to less than 3.5 g/day.

Serum albumin levels should be monitored as they reflect the severity of protein losses and help guide management of complications such as edema and thrombotic risk. Improvement in serum albumin often lags behind reduction in proteinuria.

Renal function should be assessed regularly through serum creatinine and estimated glomerular filtration rate. Stable or improving renal function is a positive prognostic sign, while declining function may indicate disease progression or drug toxicity.

Anti-PLA2R antibody levels, when positive, provide valuable information about disease activity and treatment response. Declining antibody levels often precede clinical improvement, while rising levels may indicate disease relapse. Antibody monitoring can help guide treatment decisions and predict outcomes.

Complete blood count and comprehensive metabolic panel should be monitored regularly, particularly in patients receiving immunosuppressive therapy. Specific monitoring requirements depend on the medications used, with particular attention to bone marrow suppression with alkylating agents and nephrotoxicity with calcineurin inhibitors.

Lipid levels should be monitored and managed aggressively given the increased cardiovascular risk. Blood pressure should be checked regularly and managed to target levels below 130/80 mmHg or lower if tolerated.

Infection surveillance is important in patients receiving immunosuppressive therapy, with attention to both common bacterial infections and opportunistic pathogens. Appropriate prophylaxis and vaccination strategies should be implemented.

Response to treatment is typically assessed at 3-6 month intervals, though more frequent monitoring may be necessary during the initial treatment period or when adjusting medications. Lack of response after 6-12 months of appropriate therapy may warrant consideration of alternative treatment regimens.

Prognosis and Long-term Management

The prognosis of membranous nephropathy is variable, with outcomes ranging from complete spontaneous remission to progression to end-stage renal disease. Understanding prognostic factors is essential for counseling patients and making treatment decisions.

The natural history of untreated membranous nephropathy follows a “rule of thirds”: approximately one-third of patients experience spontaneous remission, one-third maintain stable renal function with persistent proteinuria, and one-third progress to chronic kidney disease or end-stage renal disease over 10-20 years.

Several factors are associated with poor prognosis and increased risk of progression. Advanced age at presentation is consistently associated with worse outcomes, likely due to reduced regenerative capacity and increased comorbidities. Male gender is also associated with worse prognosis.

Severe proteinuria (>8-10 g/day) and hypoalbuminemia (<2.5 g/dL) at presentation are associated with increased risk of progression. Persistent heavy proteinuria despite treatment is a strong predictor of poor renal outcomes.

Renal impairment at presentation, while uncommon, is associated with worse prognosis. Patients with normal renal function at diagnosis have better long-term outcomes than those with elevated creatinine.

High levels of anti-PLA2R antibodies are associated with more severe disease and lower likelihood of spontaneous remission. Conversely, patients who become antibody-negative have better prognosis and higher rates of sustained remission.

Histological features on renal biopsy can provide prognostic information. Advanced stages with extensive basement membrane changes and the presence of interstitial fibrosis or tubular atrophy are associated with worse outcomes.

Response to treatment is the most important prognostic factor. Patients who achieve complete or partial remission have excellent long-term prognosis, while those who fail to respond to treatment have high risk of progression to end-stage renal disease.

Long-term management focuses on maintaining remission, preventing relapses, and managing complications of chronic kidney disease when present. Patients who achieve remission should continue on maintenance therapy with ACE inhibitors or ARBs and may require ongoing immunosuppressive therapy depending on the treatment regimen used.

Relapse can occur in 10-30% of patients who achieve remission, particularly those who discontinue immunosuppressive therapy. Patients should be monitored regularly for signs of relapse, including increasing proteinuria or declining renal function.

Cardiovascular disease is an important cause of morbidity and mortality in patients with membranous nephropathy, related to the hyperlipidemia, hypertension, and chronic inflammation associated with the condition. Aggressive cardiovascular risk factor modification is essential.

Chronic kidney disease complications should be managed appropriately in patients with declining renal function, including anemia management, bone disease prevention, and preparation for renal replacement therapy when indicated.

Patient education is crucial for long-term management, including understanding the chronic nature of the condition, the importance of medication adherence, recognition of signs of relapse or complications, and the need for regular follow-up care.

Summary

Membranous nephropathy is the most common cause of primary nephrotic syndrome in Caucasian adults, characterized by subepithelial immune complex deposition and glomerular basement membrane thickening. The condition is now understood to be autoimmune in most cases, with anti-PLA2R antibodies found in 70-80% of patients with primary disease.

The pathophysiology involves antibody binding to podocyte antigens, immune complex formation, complement activation, and podocyte injury leading to increased glomerular permeability. The clinical presentation is typically that of nephrotic syndrome with insidious onset of edema, proteinuria, and hypoalbuminemia.

Diagnosis requires confirmation of nephrotic syndrome, evaluation for secondary causes, and often renal biopsy showing characteristic subepithelial deposits. Anti-PLA2R antibodies are highly specific for primary disease and correlate with disease activity.

Treatment includes conservative management for all patients and immunosuppressive therapy for those at high risk of progression. Various regimens including corticosteroids with alkylating agents, calcineurin inhibitors, and rituximab have shown efficacy.

The prognosis follows a “rule of thirds” with variable outcomes ranging from spontaneous remission to progression to end-stage renal disease. Factors associated with poor prognosis include advanced age, male gender, severe proteinuria, and high antibody levels.

Long-term management focuses on maintaining remission, preventing relapses, and managing cardiovascular risk factors. Regular monitoring is essential to detect disease activity changes and treatment complications.

Clinical Pearls

1. PLA2R Antibody Significance: Anti-PLA2R antibodies are found in 70-80% of primary membranous nephropathy cases and correlate with disease activity – declining levels predict remission before clinical improvement.

2. Rule of Thirds: Natural history follows a “rule of thirds” – 1/3 spontaneous remission, 1/3 stable with persistent proteinuria, 1/3 progress to ESRD over 10-20 years.

3. Age and Gender Impact: Older age and male gender are consistently associated with worse prognosis and lower likelihood of spontaneous remission.

4. Thrombotic Risk Assessment: Patients with albumin <2.5 g/dL have significantly increased thrombotic risk, especially renal vein thrombosis – consider anticoagulation.

5. Cancer Screening Priority: Malignancy-associated MN occurs in 5-10% of patients, particularly those >65 years – age-appropriate cancer screening is essential.

6. IgG4 Predominance: Primary MN shows IgG4 predominance on immunofluorescence, while secondary forms typically show mixed IgG subclasses.

7. Treatment Timing: Consider immunosuppression after 6 months of conservative therapy in high-risk patients (declining GFR, severe symptoms, or persistent heavy proteinuria).

8. Rituximab Efficacy: Rituximab is particularly effective in anti-PLA2R positive patients and may become first-line therapy due to favorable side effect profile.

9. ACE Inhibitor Benefits: ACE inhibitors/ARBs reduce proteinuria by 30-50% and should be used in all patients unless contraindicated, regardless of blood pressure.

10. Relapse Recognition: 10-30% of patients who achieve remission will relapse – regular monitoring with proteinuria and anti-PLA2R levels is essential.

11. Spontaneous Remission Window: Most spontaneous remissions occur within the first 2 years – patients with persistent disease beyond this timeframe are less likely to remit spontaneously.

12. Cardiovascular Risk Priority: Aggressive lipid management is crucial as cardiovascular disease is a major cause of morbidity and mortality in MN patients.

Recommended Diagrams and Images:

1. Membranous Nephropathy Pathophysiology: Flowchart showing anti-PLA2R antibody binding, immune complex formation, and complement activation
2. Electron Microscopy Progression: Sequential images showing stages of basement membrane changes from early deposits to advanced “spike and dome” appearance
3. Primary vs Secondary MN Comparison: Table comparing clinical features, antibody patterns, and treatment approaches
4. Treatment Algorithm: Decision tree for conservative vs immunosuppressive therapy based on risk factors
5. PLA2R Antibody Monitoring: Graph showing correlation between antibody levels and clinical response
6. Natural History Timeline: Visual representation of the “rule of thirds” over 10-20 years
7. Immunofluorescence Patterns: Comparison of IgG subclass patterns in primary vs secondary MN
8. Risk Stratification Chart: Visual guide for identifying high-risk patients requiring immunosuppression
9. Thrombotic Risk Assessment: Algorithm for anticoagulation decisions based on albumin levels and risk factors
10. Cancer Screening Guidelines: Age-appropriate screening recommendations for MN patients

Histopathology Images:

• Light microscopy showing GBM thickening and “tram-track” appearance
• Immunofluorescence showing granular IgG and C3 deposition
• Electron microscopy demonstrating subepithelial deposits and basement membrane spikes
• PLA2R immunostaining in glomerular deposits

Clinical Photography:

• Severe pitting edema in nephrotic syndrome
• Foamy urine appearance
• Clinical signs of volume overload

Laboratory Images:

• Urinalysis showing proteinuria and lipiduria
• Anti-PLA2R antibody test results
• Lipid profile changes in nephrotic syndrome

Slide 1: Title Slide

• Title: Membranous Nephropathy
• Subtitle: The Most Common Cause of Adult Primary Nephrotic Syndrome
• NephroHub Watermark

Slide 2: Learning Objectives

• Define membranous nephropathy and pathophysiology
• Distinguish primary from secondary causes
• Understand role of PLA2R antibodies
• Describe diagnostic approach and treatment strategies
• Recognize prognosis and long-term management

Slide 3: Definition and Epidemiology

• Most common cause of primary nephrotic syndrome in Caucasian adults (20-30%)
• Peak incidence: 5th-6th decades
• Male predominance (2:1 ratio)
• Subepithelial immune complex deposition

Slide 4: Classification Overview

• Primary (75-80%): Autoimmune disease
• Secondary (20-25%): Underlying systemic condition
• Distinction crucial for treatment decisions

Slide 5: Primary MN – Autoimmune Basis

• Anti-PLA2R antibodies (70-80% of cases)
• Anti-THSD7A antibodies (5-10% of PLA2R-negative)
• Target antigens on podocyte surface
• IgG4 predominant subclass

Slide 6: Pathophysiology Overview

• Antibody binding to podocyte antigens
• Subepithelial immune complex formation
• Complement activation
• Podocyte injury and foot process effacement

Slide 7: Electron Microscopy Stages

• Stage I: Small subepithelial deposits
• Stage II: GBM spikes between deposits
• Stage III: GBM incorporation of deposits
• Stage IV: Irregular GBM thickening

Slide 8: Clinical Presentation

• Insidious onset nephrotic syndrome
• Edema (often presenting symptom)
• Heavy proteinuria (often >10 g/day)
• Normal/mildly impaired renal function
• Mild hypertension (30-50%)

Slide 9: Secondary Causes

• Malignancy (5-10%, especially >65 years)
• Autoimmune diseases (SLE, thyroiditis)
• Infections (Hepatitis B/C, syphilis)
• Medications (Gold, penicillamine, NSAIDs)

Slide 10: Diagnostic Approach

• Confirm nephrotic syndrome
• Anti-PLA2R and anti-THSD7A antibodies
• Evaluation for secondary causes
• Age-appropriate cancer screening
• Renal biopsy for definitive diagnosis

Slide 11: Laboratory Findings

• Heavy proteinuria (>3.5 g/day, often >10 g/day)
• Hypoalbuminemia (<3.0 g/dL)
• Hyperlipidemia (often severe)
• Normal/mildly elevated creatinine
• Positive anti-PLA2R (70-80% primary cases)

Slide 12: Renal Biopsy Findings

• Light microscopy: GBM thickening, normal cellularity
• Immunofluorescence: Granular IgG and C3, IgG4 predominant
• Electron microscopy: Subepithelial deposits, “spike and dome”

Slide 13: Natural History – Rule of Thirds

• 1/3: Spontaneous remission
• 1/3: Stable with persistent proteinuria
• 1/3: Progress to ESRD (10-20 years)

Slide 14: Prognostic Factors

• Good prognosis: Young age, female, low proteinuria, negative/low PLA2R
• Poor prognosis: Older age, male, heavy proteinuria, high PLA2R, renal impairment

Slide 15: Conservative Management

• Dietary: Protein restriction (0.8-1.0 g/kg/day), sodium restriction
• Edema: Loop diuretics, combination therapy
• Proteinuria: ACE inhibitors/ARBs (reduce by 30-50%)
• Lipids: Statins to target LDL <100 mg/dL

Slide 16: Anticoagulation Considerations

• High risk: Albumin <2.5 g/dL
• Renal vein thrombosis: 5-60% incidence
• Individual assessment: Balance bleeding vs thrombotic risk

Slide 17: Immunosuppressive Therapy Indications

• Persistent nephrotic syndrome after 6 months conservative therapy
• Declining renal function
• Severe symptoms impacting quality of life
• High-risk features for progression

Slide 18: Treatment Options

• Modified Ponticelli regimen: Alternating steroids and alkylating agents
• Calcineurin inhibitors: Cyclosporine, tacrolimus
• Rituximab: Emerging first-line option
• Mycophenolate: Alternative/maintenance therapy

Slide 19: Rituximab Advantages

• Effective in anti-PLA2R positive patients
• Fewer side effects than traditional regimens
• May become first-line therapy
• Requires further long-term studies

Slide 20: Monitoring Treatment Response

• Proteinuria: Primary endpoint for response
• Anti-PLA2R levels: Predict response before clinical improvement
• Complete remission: <0.3 g/day proteinuria
• Partial remission: >50% reduction, <3.5 g/day

Slide 21: Long-term Management

• Maintain remission with ACE inhibitors/ARBs
• Monitor for relapse (10-30% risk)
• Cardiovascular risk factor modification
• Regular follow-up and monitoring

Slide 22: Complications

• Thrombotic events: Renal vein thrombosis, PE
• Infections: Increased risk with immunosuppression
• Cardiovascular disease: Major cause of mortality
• Progression to CKD/ESRD

Slide 23: Key Clinical Messages

• Most common cause of adult primary nephrotic syndrome
• Anti-PLA2R antibodies revolutionized understanding
• Conservative therapy first-line for all patients
• Immunosuppression for high-risk patients
• Variable prognosis – “rule of thirds”

Slide 24: Case Study

• Clinical presentation
• Diagnostic workup including PLA2R testing
• Treatment decision-making
• Monitoring and outcome

Slide 25: Summary and Future Directions

• Autoimmune disease with specific antibody targets
• Personalized treatment based on risk factors
• Emerging role of rituximab
• Importance of long-term cardiovascular management

Question 1

What is the most common cause of primary nephrotic syndrome in Caucasian adults?

A) Minimal change disease
B) Focal segmental glomerulosclerosis
C) Membranous nephropathy
D) IgA nephropathy
E) Diabetic nephropathy

Correct Answer: C) Membranous nephropathy

Explanation: Membranous nephropathy accounts for 20-30% of primary nephrotic syndrome cases in Caucasian adults, making it the most common cause in this population.

Question 2

Which antibody is found in approximately 70-80% of patients with primary membranous nephropathy?

A) Anti-GBM antibodies
B) Anti-PLA2R antibodies
C) ANCA antibodies
D) Anti-nuclear antibodies
E) Anti-dsDNA antibodies

Correct Answer: B) Anti-PLA2R antibodies

Explanation: Anti-phospholipase A2 receptor (PLA2R) antibodies are found in 70-80% of patients with primary membranous nephropathy and are highly specific for this condition.

Question 3

What is the characteristic finding on electron microscopy in membranous nephropathy?

A) Foot process effacement only
B) Subendothelial deposits
C) Mesangial deposits
D) Subepithelial deposits with “spike and dome” appearance
E) Normal ultrastructure

Correct Answer: D) Subepithelial deposits with “spike and dome” appearance

Explanation: The characteristic electron microscopy finding in membranous nephropathy is subepithelial electron-dense deposits with basement membrane spikes projecting between deposits, creating a “spike and dome” appearance.

Question 4

What is the “rule of thirds” in membranous nephropathy?

A) 1/3 are children, 1/3 are adults, 1/3 are elderly
B) 1/3 have spontaneous remission, 1/3 remain stable, 1/3 progress to ESRD
C) 1/3 are primary, 1/3 are secondary, 1/3 are unknown
D) 1/3 respond to steroids, 1/3 need other drugs, 1/3 don’t respond
E) 1/3 have normal renal function, 1/3 have mild impairment, 1/3 have severe impairment

Correct Answer: B) 1/3 have spontaneous remission, 1/3 remain stable, 1/3 progress to ESRD

Explanation: The natural history of membranous nephropathy follows a “rule of thirds”: approximately one-third experience spontaneous remission, one-third maintain stable renal function with persistent proteinuria, and one-third progress to end-stage renal disease.

Question 5

Which medication class should be used in all patients with membranous nephropathy unless contraindicated?

A) Diuretics
B) Calcium channel blockers
C) ACE inhibitors or ARBs
D) Beta-blockers
E) Statins

Correct Answer: C) ACE inhibitors or ARBs

Explanation: ACE inhibitors or ARBs should be used in all patients with membranous nephropathy as they reduce proteinuria by 30-50% and provide cardiovascular and renal protection, regardless of blood pressure status.

Question 6

At what serum albumin level should anticoagulation be considered in membranous nephropathy?

A) <4.0 g/dL
B) <3.5 g/dL
C) <3.0 g/dL
D) <2.5 g/dL
E) <2.0 g/dL

Correct Answer: D) <2.5 g/dL

Explanation: Anticoagulation should be considered in patients with serum albumin <2.5 g/dL due to significantly increased thrombotic risk, particularly renal vein thrombosis.

Question 7

Which age group has the highest risk of malignancy-associated membranous nephropathy?

A) Children (<18 years)
B) Young adults (18-40 years)
C) Middle-aged adults (40-65 years)
D) Elderly (>65 years)
E) All age groups equally

Correct Answer: D) Elderly (>65 years)

Explanation: Malignancy-associated membranous nephropathy occurs in 5-10% of patients overall but is particularly common in those over 65 years of age, requiring age-appropriate cancer screening.

Question 8

What is the predominant IgG subclass in primary membranous nephropathy?

A) IgG1
B) IgG2
C) IgG3
D) IgG4
E) Mixed subclasses

Correct Answer: D) IgG4

Explanation: Primary membranous nephropathy, particularly PLA2R-associated disease, shows predominant IgG4 deposition on immunofluorescence, which helps distinguish it from secondary forms.

Question 9

When should immunosuppressive therapy be considered in membranous nephropathy?

A) Immediately upon diagnosis
B) After 1 month of conservative therapy
C) After 3 months of conservative therapy
D) After 6 months of conservative therapy in high-risk patients
E) Only if renal function is declining rapidly

Correct Answer: D) After 6 months of conservative therapy in high-risk patients

Explanation: KDIGO guidelines recommend considering immunosuppressive therapy after 6 months of conservative therapy in patients with persistent nephrotic syndrome, particularly those with declining renal function or severe symptoms.

Question 10

Which factor is associated with the best prognosis in membranous nephropathy?

A) Male gender
B) Advanced age at presentation
C) Heavy proteinuria (>10 g/day)
D) Young age and female gender
E) High anti-PLA2R antibody levels

Correct Answer: D) Young age and female gender

Explanation: Young age and female gender are consistently associated with better prognosis and higher likelihood of spontaneous remission in membranous nephropathy.

Visual Learning Workflow